Personal information

Verified email addresses

CAR T cells, Immunotherapy, Cell-based Therapy, Cancer, Oncology, CRISPR/Cas9, Immuno-oncology
United States

Biography

Muhammad Sadeqi Nezhad is a cancer researcher at Clinical and Translational Science Institute (CTSI), University of Rochester Medical Center, New York, USA. Currently, he is working with a great team on development of cancer therapeutics for pancreatic cancer patients with primary and metastatic tumors at Wilmot Cancer Institute. One of his research desires is to develop novel therapeutic approaches for cancer patients with metastatic tumor cells.

Besides the cancer research, He, as an entrepreneur, is seeking to find pains in his research area to design and develop a novel therapeutic or diagnostic technology with great unmet market need.

Muhammad has worked with several state-of-the-art and sophisticated Technologies.

His Areas of Expertise Are:

1. CRISPR/Cas9 Technology (Knock-In, Knock-out, and Knock-down)
2. Viral production (Lentivirus, Retrovirus, and Adeno Associated Virus)
3. Biotin Ligase or BioID Technology, a Tool for Protein-Proximity Labeling in Living Cells
4. Degron Technology for discovering and validating new disease targets
5. Molecular Cloning
6. Electroporation, Transfection, and Transduction
7. Orthotopic Tumor Model Development
8. And, Many more routine lab experiments and techniques, such as PCR, RT-PCR, Flow Cytometry, Western Blot, etc.

He also performed peer review for more than 30 times, and He has been a Peer Reviewer of the following Journals:

1. Cell Press, STAR protocols
2. Springer Nature, Stem Cell Reviews and Reports (IF: 6.43)
3. Frontiers in Immunology (IF: 7.561)
4. Elsevier, Biomedicine & Pharmacotherapy (IF: 7.419)
5. Cambridge University Press, Expert Reviews in Molecular Medicine (IF: 5.233)
6. Elsevier, Computers in Biology and Medicine (IF: 4.589)
7. As well as other prominent scientific Journals

He also participated in a research topic development for “Frontiers in Immunology” journal with eminent researchers from MD Anderson Cancer Center, etc. The research topic led to 8 publications.

Activities

Education and qualifications (1)

University of Rochester Medical Center: Rochester, New York, US

2022-03-01 to present | PhD (Cancer center)
Education
Source: Self-asserted source
Muhammad Sadeqi Nezhad

Works (7)

Poly (beta‐amino ester) as an in vivo nanocarrier for therapeutic nucleic acids

Biotechnology and Bioengineering
2023-01 | Journal article
Contributors: Muhammad Sadeqi Nezhad
Source: check_circle
Crossref

Strengthening the CAR‐T cell therapeutic application using CRISPR/Cas9 technology

Biotechnology and Bioengineering
2021-10 | Journal article
Contributors: Muhammad Sadeqi Nezhad; Mahboubeh Yazdanifar; Meghdad Abdollahpour‐Alitappeh; Arash Sattari; Alexander Seifalian; Nader Bagheri
Source: check_circle
Crossref

Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products

Pharmaceutical Research
2021-06 | Journal article
Contributors: Muhammad Sadeqi Nezhad; Meghdad Abdollahpour-Alitappeh; Behzad Rezaei; Mahboubeh Yazdanifar; Alexander Marcus Seifalian
Source: check_circle
Crossref

An overview of the prominence of current diagnostic methods for diagnosis of COVID-19

AIMS Allergy and Immunology
2020 | Journal article
Part of ISSN: 2575-615X
Source: Self-asserted source
Muhammad Sadeqi Nezhad

Chimeric Antigen Receptor Based Therapy as a Potential Approach in Autoimmune Diseases: How Close Are We to the Treatment?

Frontiers in Immunology
2020-11-26 | Journal article
Part of ISSN: 1664-3224
Source: Self-asserted source
Muhammad Sadeqi Nezhad

Biological Aspects and Clinical Applications of Mesenchymal Stem Cells: Key Features You Need to be Aware of.

Current Pharmaceutical Biotechnology
2020-09-07 | Journal article
Part of ISSN: 1389-2010
Source: Self-asserted source
Muhammad Sadeqi Nezhad
grade
Preferred source (of 2)‎

Development and biological assessment of MMAE-trastuzumab antibody–drug conjugates (ADCs)

Breast Cancer
2020-09-05 | Journal article
Part of ISSN: 1340-6868
Contributors: Sajad Yaghoubi; Tohid Gharibi; Mohammad Hossein karimi; Muhammad Sadeqi Nezhad; Alexander Seifalian; Reza Tavakkol; Nader Bagheri; Asiyeh Dezhkam; Meghdad Abdollahpour-Alitappeh
Source: Self-asserted source
Muhammad Sadeqi Nezhad via Crossref Metadata Search

Peer review (9 reviews for 2 publications/grants)

Review activity for STAR protocols. (2)
Review activity for Stem cell reviews. (7)